Autophagy facilitates the adaptation to nutritional stress. Here, we show that short-term starvation of cultured cells or mice caused the autophagy-dependent cellular release of acyl-CoA-binding protein (ACBP, also known as diazepam-binding inhibitor, DBI) and consequent ACBP-mediated feedback inhibition of autophagy. Importantly, ACBP levels were elevated in obese patients and reduced in anorexia nervosa. In mice, systemic injection of ACBP protein inhibited autophagy, induced lipogenesis, reduced glycemia, and stimulated appetite as well as weight gain. We designed three approaches to neutralize ACBP, namely, inducible whole-body knockout, systemic administration of neutralizing antibodies, and induction of antiACBP autoantibodies in mice. ACBP neutralization enhanced autophagy, stimulated fatty acid oxidation, inhibited appetite, reduced weight gain in the context of a high-fat diet or leptin deficiency, and accelerated weight loss in response to dietary changes. In conclusion, neutralization of ACBP might constitute a strategy for treating obesity and its co-morbidities.
INTRODUCTION
Macroautophagy (in short ''autophagy'') contributes to the maintenance of cellular and organismal homeostasis by mediating the turnover of dispensable cytoplasmic structures (Levine and Kroemer, 2019) . In particular, autophagy facilitates the adaptation to nutritional stress by degrading intracellular macromolecules including proteins, lipids, and glycogen into small molecules that fuel energy metabolism (Galluzzi et al., 2014) .
Derangements of autophagy-and in particular its inhibitionplay a role in all major human diseases including cancer (Amaravadi et al., 2016) , cardiovascular disease (Henning and Brundel, 2017) , and neurodegeneration (Menzies et al., 2017) , as well as obesity and its co-morbidities (Ló pez-Otín et al., 2016) . Thus, both genetic and pharmacological inhibition of autophagy compromise weight loss induced by starvation and develop obesity and diabetes He et al., 2013) . Circumstantial evidence indicates that obesity is associated with suppressed autophagic flux (Boudoures et al., 2017; Mizunoe et al., 2017; Potes et al., 2017) , in line with the fact that its metabolic correlates including hyperglycemia (Roberts et al., 2014) , hyperlipidemia (Koga et al., 2010) , and hyperinsulinemia (Gulati and Thomas, 2007) actually inhibit autophagy. The etiological link between excessive adiposity and accelerated manifestation of age-associated diseases might involve disabled autophagy (Ló pez-Otín et al., 2016) .
Although autophagy is mostly studied as a cell-autonomous event, there is evidence that autophagy may affect the communication between cells as well. Thus, autophagy regulates the turnover of cell surface receptors, as exemplified for EGFR (Wei et al., 2013) and cannabinoid receptors (He et al., 2013) . Moreover, some factors are released from cells in an autophagy-dependent fashion. This applies to adenosine triphosphate (ATP), the apoptosis-associated release of which depends on the induction of premortem autophagy, with vast consequences for the attraction of myeloid cells into the vicinity of dying cells (Qu et al., 2007; Vacchelli et al., 2015) . Moreover, the cellular secretion of several leaderless proteins (which, by definition, can only be released through an unconventional pathway bypassing Golgi) is strongly associated with, and probably depends on, autophagy (Dupont et al., 2011; Ponpuak et al., 2015; Zhang and Schekman, 2013) . One such leaderless protein is the phylogenetically ancient factor acyl-CoA-binding protein (ACBP), also known as diazepam-binding protein (DBI) (Duran et al., 2010; Manjithaya et al., 2010) . ACBP from human or mouse origin is a small protein of 87 amino acids that has two distinct functions, namely, as ACBP within cells-where it binds to long-chain acyl-CoA molecules, regulating lipid metabolism -and as DBI outside cells-where the protein can interact with the benzodiazepine-binding site of the gamma-aminobutyric acid (GABA) type A receptor, GABA A R, and modulate its activity (Bormann, 1991; Christian et al., 2013) .
Here, we addressed the question as to whether autophagydependent ACBP secretion occurs in mammals and whether ACBP might participate in autophagy regulation and lipid metabolism. We show that ACBP is not only involved in the control of autophagy, but that it also affects general lipid metabolism. This notion is based on the observations that ACBP levels correlate with human body mass index; that increasing ACBP levels in mice triggers lipogenesis, food intake, and weight gain; and that its neutralization increases lipolysis, reduces food intake post-starvation, and causes weight loss in mice.
RESULTS

Autophagy-Dependent Release of ACBP from Human Cells and Mouse Organs
We investigated whether mammalian cells would release ACBP through a similar pathway as yeast (Kinseth et al., 2007) . Cells maintained in nutrient-free (NF) condition or treated with rapamycin, two potent stimulators of autophagy, underwent a bona fide autophagic response-as indicated by the lipidation of microtubule-associated protein 1 light chain 3 beta (MAP1LC3B; best known as LC3), the redistribution of a GFP-LC3 fusion protein toward autophagosomes, and the degradation of the autophagy substrate sequestosome 1 (SQSTM1/p62) (Klionsky et al., 2016) . This response was accompanied by the depletion of intracellular ACBP detectable by immunoblot analyses of cellular extracts ( Figures 1A, 1B , and S1A-S1C), immunofluorescence staining (Figures S1D-S1G), image cytometry (Figures S1H and S1I), or cytofluorimetric analysis (Figures S1J-S1M). The decrease of ACBP protein induced by short-term (4 h) starvation was not accompanied by an equivalent decrease of ACBP mRNA ( Figure 1C ). ACBP decrease was suppressed by the knockdown of the essential autophagy genes ATG5, ATG7, ATG10, or Beclin 1; by the addition of lysosomal inhibitors like bafilomycin A1 (BafA1) and chloroquine; or by inhibiting phosphatidylinositol 3-kinase catalytic subunit type 3 with wortmannin ( Figures 1A, 1B , and S1A-S1I). In contrast, ACBP depletion from cells was not inhibited by brefeldin A, an inhibitor of conventional protein secretion, or by the silencing of several genes (STX3, STX4, TRIM10, SNAP29, SNAP23, TRIM16, or SEC22B) involved in the unconventional secretion of interleukin-1b (Kimura et al., 2017) (Figures S1J-S1M ). The NFinduced, BafA1-inhibitable release of soluble ACBP into the supernatant could be detected by means of an enzyme-linked (D and E) ELISA-detectable ACBP in culture media of primary mouse hepatocytes (n = 4 mice per group), human cancer cell lines (D) (n = 4 replicates), and human peripheral blood mononuclear cells (PBMCs) (n = 3 individuals) (E) after the indicated treatments. (F-J) Autophagy-dependent release of ACBP from mouse organs into the plasma. Representative pictures (F) and quantification (G) of immunofluorescence of ACBP in livers of WT or Atg4b À/À mice after 24 h of starvation (unfed). Representative immunoblot (3 representative lanes) (H) and quantification (n = 3 to 5 mice per group) (I) of ACBP levels determined in visceral fat (n = 3 to 5 mice per group). ELISA-detectable ACBP levels in plasma (n = 8 mice per group) (J).
(K-N) Effects of extracellular ACBP on autophagy in vivo. Immunoblots and densitometric quantification of LC3 lipidation in liver tissues from mice treated with an ACBP-neutralizing antibody (AntiACBP) (K and L) or recombinant ACBP (RecACBP) (M and N), respectively, with or without the autophagy flux inhibitor leupeptin (leu) (n = 3 mice per group). Experiments in this figure were performed three times. Results are displayed as box and whisker plots, which show mean, first and third quartiles, and maximum and minimum values (C-E and J) or mean ± SEM (B, G, I, L, and N). For statistical analyses, p values were calculated by two-way ANOVA with Sidak (B, D, G, I, and J) or two-tailed unpaired Student's t test (C, E, L, and N) . Symbols indicate statistical comparisons with the control condition (*p < 0.05, **p < 0.01, ***p < 0.001 Figure S1C ) and did not require de novo protein synthesis ( Figure S1N ). This BafA1-inhibitable ACBP release was observed in primary hepatocytes, peripheral blood mononuclear cells, and multiple human cell lines cultured in NF media ( Figures 1D, 1E , S1H, and S1I). The intracellular levels of ACBP decreased in several organs from autophagy-competent wild-type (WT) mice, but not in Atg4b À/À mice (a well-established model of autophagy deficiency) (Mariñ o et al., 2010) , subjected to 24 h of starvation (Figures 1F-1I , S2A, and S2B), a condition that induces autophagy in most tissues from WT mice (Mizushima et al., 2004) . In parallel, starvation led to an increase in plasma ACBP levels in WT mice, but not in autophagy-deficient Atg4b À/À mice ( Figure 1J) . Moreover, the starvation-induced surge in plasma ACBP was inhibited by injection of dimethyl a-ketoglutarate and leupeptin ( Figure S2C ), which suppress the initiation (Mariñ o et al., 2014) and termination (Esteban-Martinez and Boya, 2015) of autophagy, respectively.
Autophagy-Regulatory Effects of Intracellular and Extracellular ACBP Pools
Intraperitoneal (i.p.) injection of an antibody that neutralizes extracellular ACBP (antiACBP) induced autophagy in the liver ( Figures 1K and 1L ), while the systemic intravenous (i.v.) administration of recombinant ACBP (recACBP) inhibited autophagy ( Figures 1M and 1N) . Notably, recACBP enhanced the accumulation of SQSTM1, the phosphorylation of protein kinase B (best known as AKT1), and that of the mechanistic target of rapamycin complex-I (MTORC1) substrate p70 S6K in the mouse liver in vivo ( Figure S2D ) and in primary human hepatocytes in vitro, together with the phosphorylation of EIF4BP1, another target of MTOR (Figures S2E and S2F) . AKT inhibition overcame MTORC1 activation and autophagy inhibition by recACBP ( Figure S2F ).
Depletion of ACBP by specific small interfering RNAs inhibited NF-driven autophagy and stimulated autophagy-inhibitory MTORC1 activity in human cancer cells in vitro (Figures S3A and S3C) , while transfection-enforced ACBP overexpression stimulated autophagic flux, as indicated by the redistribution of GFP-LC3 to cytoplasmic puncta, and the lipidation of LC3 (LC3-II) ( Figures S3B and S3D ). However, when ACBP was depleted (thus autophagy was inhibited) from a majority of human H4 cells that were co-cultured with a minority of ACBP-expressing cells (which are still autophagy-competent), the latter exhibited increased autophagic flux as assessed by measuring GFP-LC3 punctae in the absence or presence of BafA1 ( Figures  S3E and S3F ), confirming the previous in vivo results in which we observed that extracellular ACBP inhibits autophagy. Indeed, the addition of antiACBP to cultured human cells stimulated autophagy ( Figures S3G and S3H) , while the addition of recACBP robustly inhibited NF-driven autophagy ( Figures S3I and S3J ).
Metabolic Impact of Increasing ACBP Levels
Since extracellular ACBP suppresses autophagy, we investigated whether extracellular ACBP might also affect general metabolism. To this aim, recACBP protein and an antiACBP antibody were injected into fed and starved mice, respectively, and plasma metabolomics were profiled 2 h later. While recACBP reduced glycemia, ACBP neutralization reversed the starvation-induced reduction in blood glucose levels and exacerbated the increase in circulating 2-hydroxybutyric acid ( Figure 2A ; Table S1 ). We therefore decided to investigate the effects of ACBP on wholebody metabolism while focusing on energy metabolism.
Increasing ACBP levels, by systemic i.v. injection of recACBP or hydrodynamic injection of plasmids containing a cDNA-ACBP into mice, which caused hepatocyte overexpression of ACBP and increased plasma ACBP levels, stimulated food intake without affecting insulin levels ( Figures 2B and S4A-S4D) . Accordingly, i.v. injected recACBP rapidly activated orexigenic lateral hypothalamus neurons, as indicated by the nuclear localization of the transcription factor FOS detected by immunohistochemistry ( Figures 2C and S4E ). Leptin and ghrelin are important endocrine regulators of energy balance and food intake (Farooqi et al., 2001; Inui, 2001) . RecACBP injection reduced circulating leptin ( Figure S4F ) but did not affect ghrelin levels ( Figure S4G ). Of note, ob/ob mice (lacking leptin) showed an increase in circulating ACBP levels in response to starvation ( Figure S4H ). Moreover, recACBP reduced glucose levels in ob/ob mice ( Figure S4I ), yet failed to further enhance the constitutive hyperphagy of ob/ob mice, which was reduced upon leptin injection (Figure S4J) . However, injection of a high dose of recombinant leptin ( Figure S4K ) failed to reverse the drop in glycemia ( Figure S4L ) and the hyperphagy induced by recACBP injection ( Figure S4M ), suggesting that ACBP can operate independently from the leptin system. Of note, recACBP injection caused the rapid (within 30 min) increase of liver ACBP levels and glucose transporter solute carrier family 2 member 1 (SLC2A1; best known as GLUT1) and also induced hepatic expression of peroxisome proliferatoractivated receptor gamma (PPARG), which stimulates lipogenesis via fatty acid synthase (FASN) transactivation ( Figures 2D  and S4N ). The upregulation of FASN and PPARG in the liver or white adipose tissue (WAT) was observed in starved mice, meaning that it is not secondary to an increased food intake (Figures S4O and S4P) . In mice with ad libitum access to food, recACBP reduced fatty acid oxidation, as determined by wholebody respirometry ( Figure 2E ). Systemic injection of recACBP or transgenic expression of Acbp reduced blood glucose levels ( Figures 2F and S4Q ) and exacerbated the ability of insulin to reduce glycemia in fed mice ( Figure S4R ), as it enhanced the incorporation of 14 C atoms from 2-deoxyglucose into visceral fat ( Figure S4S ). Mass spectrometric fluxomics with 13 C glucose confirmed the increased glucose uptake into adipose tissue upon recACBP injection even in the absence of insulin injection ( Figure S4T ). The transient drop in blood glucose induced by recACBP injection was abolished by a pharmacological GLUT1 inhibitor ( Figure S4U ). Importantly, the reversal of the ACBPinduced reduction in glycemia by i.p. injection of glucose (Figure 2G) prevented the increase of food intake ( Figure 2H ). Thus, ACBP stimulates glucose uptake, which may account for the blood glucose reduction that ultimately drives feeding behavior in mice and reduces the ACBP-mediated activation of orexigenic neurons ( Figure S4V ).
Effects of ACBP Depletion or Neutralization
To neutralize the extracellular pool of ACBP, we injected mice with suitable monoclonal or polyclonal antiACBP antibodies into the peritoneal cavity. This maneuver reduced food intake post-starvation ( Figures 3A and S5A ) and increased plasma glucose in fed as well as in starved mice (Figures 3B and S5B) . ACBP blockade by i.p. injected antibodies rapidly activated neurons in the anorexigenic ventromedial nucleus, and lack of FOS expression was observed in neurons of the orexigenic lateral hypothalamic area (Figures S5C-S5E ). ACBP neutralization caused reduction of the hepatic protein levels of ACBP, PPARG, FASN, and the inhibitory phosphorylation of sterol regulatory elementbinding transcription factor 1 (SREBF1) ( Figures 3C and S5F) , and increased plasma adiponectin levels ( Figure S5G ), suggesting a global activation of lipolysis. Indeed, WAT from antiACBP antibody-injected mice generated more glycerol that WAT from isotype-injected control mice ( Figure 3D ). AntiACBP injection Table S1 . (B-H) Metabolic effect of increasing ACBP in vivo. (B) Cumulative (cum.) food intake was monitored after recACBP injection (n = 10-13 mice per group). (C) Representative picture of nuclear FOS expression in neurons from lateral hypothalamus (LH) (n = 3 mice per group). (D) Representative immunoblots of ACBP, peroxisome proliferator-activated receptor gamma (PPARG), fatty acid synthase (FASN), glucose transporter solute carrier family 2 member 1 (SLC2A1; best known as GLUT1), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in liver tissue (n = 5 mice per group). (E) Fatty acid (FA) oxidation measured by respirometry over 24 h. Area under the curve (AUC) for statistical comparison (n = 3 mice per group). (F) Glycemia after recACBP injection (n = 5-8 mice per group). (G and H) Glycemia (G) and cumulative food intake (H) were monitored during 2 h of recACBP injection in presence or absence of glucose (Glu) (n = 5 mice per group). Experiments in this figure were performed three times. Results are displayed as heatmap (A) or box and whisker plots, which show mean, first and third quartiles, and maximum and minimum values (B-H). Open circles (B) indicate each mouse used in each experiment. For statistical analysis, p values were calculated by Mann-Whitney U test (A), two-tailed unpaired Student's t test (B, E, and F), or two-way ANOVA with Sidak (H). Symbols indicate statistical comparisons with controls (*p < 0.05,**p < 0.01,***p < 0.001). 2-hydroxybutyric acid, aHB; intravenously, i.v.; fornix, F; grams, g; kilodaltons, kDa. See also Figure S4 and Table S1 . (legend continued on next page) caused a marked raise in blood glucose levels after glycerol injection ( Figure 3E ) and a more pronounced conversion of 13 C-labeled glycerol into hepatic glycerol-3-phosphate, as well as into glucose in the liver and in the plasma ( Figure 3F ). ACBP neutralization enhanced whole-body fatty acid oxidation in baseline ( Figure 3G ) and starved conditions ( Figure 3H ). Accordingly, ACBP neutralization also augmented the starvation-associated hepatic mobilization of lipids from adipose tissue ( Figures 3I  and 3J ), yet did not prevent hepatic glycogen depletion (Figures S5H and S5I) . In spite of the increase in blood glucose induced by ACBP neutralization, starved mice injected with antiACBP exhibited a decrease in plasma insulin, C-peptide, and gastric inhibitory peptide (GIP) levels ( Figures S5J-S5L ).
Constitutive knockout of Acbp in mice results in embryonic death (Landrock et al., 2010) or multiple defects including epidermal barrier dysfunction , depending on the genetic background. We generated mice in which Acbp can be conditionally knocked out by tamoxifen injection (based on the Tam-inducible, Cre recombinase-mediated excision of floxed Acbp) (Figures S5M and S5N) . In contrast to starved ACBP-expressing controls, ACBP-depleted mice were able to maintain glucose levels in the normoglycemic range ( Figure 3K ) and circulating ketone bodies were increased after 24 h of starvation ( Figure S5O ). The metabolomic changes induced by the Acbp knockout were very similar to those induced by starvation in normal mice, both in plasma ( Figure 3L ) and in brown adipose tissue ( Figure 3M ).
Altogether, these results confirm that ACBP plays a critical role in regulating glucose and lipid metabolism in addition to modulating feeding behavior.
ACBP Levels in Human and Mouse Obesity
In a cohort of 52 patients with anorexia nervosa, plasma ACBP concentrations were lower than in 14 age-and sex-matched controls with a normal body mass index (BMI) ( Figure 4A ), confirming a prior report on a group of 24 anorexic patients (Conti et al., 2013) . More importantly, ACBP concentrations were significantly elevated in obese individuals ( Figure 4B ), and ACBP levels were reduced along with weight loss 12 months after bariatric-surgery in another group of patients ( Figure 4C ). Thus, circulating ACBP levels correlated with BMI across several patient subsets ( Figure 4D ). Elevated ACBP levels in obese individuals correlated with augmented serum insulin ( Figure 4E ) and aspartate transaminase levels ( Figure 4F ), which are indicative of (pre-)diabetes and liver dysfunction, respectively. Weight loss upon 6 weeks of hypocaloric regimen (Cotillard et al., 2013) or bariatric intervention led to a temporary reduction of ACBP mRNA levels in the periumbilical adipose tissue from obese individuals ( Figures 4G and 4H ).
Leptin-deficient ob/ob mice (which are hyperphagic and become obese even on a normal diet) manifested an increase in Acbp mRNA expression and protein levels in liver and adipose tissue ( Figures 5A-5D ) as well as an increase in circulating ACBP concentrations as compared to their lean controls ( Figure 5E ). Normal mice rendered obese by a high-fat diet (HFD) also manifested an increase in ACBP protein levels in plasma ( Figure 5F ), liver, and adipose tissue ( Figures 5G and 5H ). Conversely, starvation caused a decrease in Acbp mRNA (Figures 5I and 5J) and ACBP protein in liver and fat ( Figures 1F-1I) .
Altogether it appears that a long-term increase in caloric uptake and adiposity, as observed in human obesity, HFD-fed mice, or ob/ob mice, is coupled to the transcriptional upregulation of ACBP gene expression and a rise in both intracellular and extracellular ACBP protein.
Metabolic Impact of Modifications of ACBP Levels
In the next step, we determined whether manipulation of ACBP would be sufficient to affect body mass. Hydrodynamic injection of plasmids containing a cDNA coding for ACBP into mice caused significant weight gain. This effect was seen with an Acbp encoding a strong short-time expression vector, pCMV6, for several days ( Figure 5K ) as well as with a weaker long-term expression vector, pLIVE, that elevates ACBP levels for several months ( Figure 5L ). Thus, experimental augmentation of ACBP triggers weight gain. Importantly, the Acbp knockout reduced body mass in several conditions. Acbp knockout increased weight loss upon starvation ( Figure 5M ) and attenuated the HFD-induced weight gain ( Figure 5N ). Moreover, mice that had been rendered obese on an HFD lost more weight when switching to a normal diet that was accompanied by Acbp knockout ( Figure 5O ).
Next, we induced the production of ACBP-neutralizing autoantibodies by repeatedly immunizing mice with ACBP coupled to keyhole limpet hemocyanin (KLH) together with a potent adjuvant (Semerano et al., 2016) (Figures S6A and S6B ). Autoimmunization against ACBP leads to enhanced weight loss during starvation ( Figure 6A ). The weight gain that generally characterizes ob/ob mice or WT mice receiving a standard chow or HFD, (D-F) Lipolysis and gluconeogenesis induced by ACBP neutralization. White adipose tissue (WAT) lipolysis activity, measured as glycerol production (n = 5 mice per group) (D). Gluconeogenic capacity was measured by i.p. glycerol tolerance tests (E) in non-fasted mice. The area under the curve (AUC) was calculated (n = 4 mice per group without glycerol and n = 8 to 9 mice per group with glycerol injection. Mass spectrometry analysis (F) in mice receiving 13 C-glycerol (gly) alone or together with antiACBP as the presence of 13 C-glycerol-3-P in liver and respectively, was reduced upon autoimmunization against ACBP ( Figures 6B-6E ). Coherently, in ob/ob mice treated with KLH-ACBP, we observed an increase in carnitine fatty acid esters (and a decrease of phosphatidylcholine) and free fatty acids in plasma (Figures 6F and S6C; Table S2 ). Moreover, the surge of antiACBP autoantibodies in HFD mice was accompanied by a reduction of absolute fat mass ( Figure 6G ) and the endogenous mRNA levels of Acbp and the lipogenic gene Pparg in the liver ( Figure 6H ). Additionally, HFD-fed mice subjected to ACBP-targeted autoimmunization exhibited less hepatosteatosis (Figures 6I and 6J) and reduced hepatic levels of FASN ( Figures S6D and  S6F ). In the brown adipose tissue (BAT) of HFD-fed mice, the induction of autoantibodies against ACBP was associated with increased uncoupling protein 1 (UCP1) levels, carnitine palmitoyltransferase 1A (CPT-1A, which is required for fatty acid uptake by mitochondria) (Figures S6E and S6G) , and total protein content ( Figure S6H ). Of note, ACBP neutralization also reduced the median size of WAT adipocytes ( Figures 6K and 6L ), as it normalized the glucose tolerance test in HFD-fed mice ( Figure 6M ).
DISCUSSION
The unconventional secretion of ACBP has been previously described in yeast (Kinseth et al., 2007) and mammals, more specifically in rabbit glial cells (Qian et al., 2008) . However, the underlying mechanisms have remained enigmatic. Here, we provide evidence that autophagy is coupled to the release of intracellular ACBP into the extracellular space in different (non-glial) human cell lines and human peripheral blood mononuclear cells as well as in several mouse organs. Moreover, we propose a physiological explanation to the link between autophagy induction and the release of ACBP from the intracellular compartment when an energy deficiency occurs.
Of note, we observed a remarkable correlation between ACBP (both intracellular and extracellular levels) and body mass in humans and mice. Thus, in adolescents with anorexia nervosa, the circulating ACBP levels are low, while restrictive dietary interventions in mice decrease intracellular Acbp mRNA and ACBP (A-E) Weight measurements of mice treated with keyhole limpet hemocyanin (KLH) alone or conjugated to recombinant ACBP (KLH-ACBP) after 1 or 2 days of starvation (Unfed) (n = 8 to 9 mice per group) (A), after a period of normal diet (n = 7 mice per group) (B), or in ob/ob mice (n = 7 to 9 mice per group) (D) or high-fat diet (HFD) (E). Percentage of body fat after a period of normal diet was also measured (n = 7 mice per group) (C).
(F) Heatmap clustered by Euclidean distance of changes in plasma metabolite concentrations depicted as log 2 fold change (FC) in obese (ob/ob) mice injected with KLH alone or KLH conjugated to recombinant ACBP (KLH-ACBP) (n = 8 to 10 mice per group). See also Figure S6C . The full dataset is reported in Table S2 .
(G) Representative images of the whole-body composition analysis of KLH and KLH-ACBP mice after normal diet or HFD.
(H) Acbp and Pparg mRNA expression in liver from mice vaccinated with KLH or KLH-ACBP and fed with HFD (n = 5 mice per group).
(legend continued on next page) protein levels in fat and liver tissues. Intriguingly, deletion of Acbp or ACBP protein neutralization with endogenous or exogenous antibodies increased autophagy, leading to a parallel dropping of ACBP in the intracellular space and a lipolytic response in mice, enhanced fatty acid oxidation, and stimulated browning of adipose tissue. In turn, these changes generated a temporary hyperglycemia, likewise due to the enhanced conversion of glycerol into glucose, and a consequent anorexic response, which finally limited the weight gain, lipogenesis, adiposity, and hepatosteatosis induced by HFD. Thus, antibody-mediated neutralization of ACBP induced a metabolic response that mimicked that found in conditions of caloric restriction. Obese patients exhibited elevated plasma levels of ACBP, while a reduction in the ACBP mRNA and ACBP plasma protein levels is observed in these patients after an important weight loss. Likewise, obese mice showed an increase in the expression of Acbp mRNA and ACBP protein levels in white adipose tissue, liver, and plasma. These results agree with previous findings describing a decrease of ACBP levels in rat liver after 24 h fasting, and augmentations of hepatic ACBP after a 48 h HFD (Bhuiyan et al., 1995) . Moreover, ACBP has been reported to favor the differentiation of preadipocytes into adipocytes (Hansen et al., 1991) . Obesity is associated with the activation of PPARG (Stienstra et al., 2007) , which potently induces lipogenesis and transactivates ACBP (Neess et al., 2006) . Thus, a long-term increase in body mass may induce an elevation in ACBP by transcriptional upregulation. Of note, murine obesity, whether induced by diet (HFD) or by overeating a normal diet due to leptin deficiency (ob/ob), led to similar elevations in Acbp mRNA and protein expression. Accordingly, the rise of ACBP levels in mice (resulting from the expression of ACBP-encoding transgenes in hepatocytes or from the injection of recACBP) stimulated a lipogenic response, an increase of glucose uptake into adipose tissue, an increase in food intake, and weight gain. The regulation of food intake and energy metabolism were not depending on leptin, and the orexigenic effect of ACBP seemed to be associated with a temporary reduction in circulating blood glucose levels, as indicated by the fact that glucose injection blunted the ACBP-induced food intake.
Obesity is linked to autophagy inhibition (Boudoures et al., 2017; Mizunoe et al., 2017; Potes et al., 2017) , meaning that altered autophagic flux may not explain the augmentation in circulating ACBP but may contribute to the increment of the intracellular ACBP levels. In addition, although we do not know the in-depth role of the extracellular protein, the experiments performed in mice suggest that the obesity-associated rise in plasma ACBP may contribute to autophagy inhibition, which in turn could counteract weight loss and promote weight gain Mariñ o et al., 2014) . Thus, it is possible that extracellular ACBP is part of a feedback regulatory system that self-limits autophagy (Simon et al., 2017).
Our observation that systemic administration of recACBP has orexigenic effects contrasts with prior reports showing that stereotactic or intrathecal administration of proteolytic ACBP fragments into the brain is anxiogenic and anorexigenic (Guillebaud et al., 2017; Lanfray et al., 2013) . We believe that several reasons plead in favor of a role for ACBP as a peripheral (rather than central nervous) stimulator of lipo-anabolism and that the modulation of appetite and obesity observed in this work occurs as consequence of ACBP effects on systemic metabolism. First, the hepatic expression of transgenic ACBP reduced glucose levels and enhanced food intake. Second, peripherally (i.v.) administered recACBP, which does not cross the blood-brain barrier (Barmack et al., 2004) , provoked rapid (within 30 min) metabolic effects leading to enhanced glucose uptake into peripheral tissues, reduced glycemia, and enhanced food intake. Third, the ACBPinduced activation of orexigenic neurons and enhanced feeding was inhibited in conditions of glucose clamp, as a result of the i.p. injection of glucose. Fourth, neutralization of extracellular ACBP by antibodies (which cannot cross the blood-brain barrier) was able to rapidly reduce the activity of orexigenic neurons and activate anorexigenic neurons, again pleading in favor of a peripheral role for ACBP in metabolism and appetite control. Altogether, it appears that ACBP may influence metabolism through systemic effects, independently from its central-nervous impact.
Based on these findings obtained in human and mice, we speculate that, if the long-term blockade of ACBP was exempt of detrimental side effects and constituted a desirable therapeutic goal, autoimmunization against ACBP might be useful for the prevention or treatment of obesity with its co-morbidities.
Limitations of Study
Although the results obtained in mice clearly plead in favor of a role for ACBP in stimulating appetite and obesity, the role of ACBP in human pathophysiology remains to be corroborated by clinical trials. So far, the human data are merely correlative, indicating that ACBP plasma levels are abnormally low in anorexia nervosa and excessively high in obese patients. However, it has to be determined whether an external supply of ACBP may stimulate appetite in anorexic patients. Similarly, the possibility to inhibit ACBP (or its receptor) for controlling excessive appetite and weight gain in obese patients requires further in-depth investigation.
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Plasmids generated in this study will be made available upon reasonable request. These plasmids will be deposited at Addgene. The mouse line was generated by Ozgene and can be purchased from this supplier.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Chemicals, Cell Lines, Culture Conditions Unless otherwise indicated, media and supplements for cell culture were purchased from Gibco-Invitrogen (Carlsbad, CA, USA), plasticware from Corning B.V. Life Sciences (Schiphol-Rijk, The Netherlands). All cell lines were cultured at 37 C under 5% CO 2 , in medium containing 10% fetal bovine serum, 100 mg/L sodium pyruvate, 10 mM HEPES buffer, 100 units/mL penicillin G sodium and 100 mg/mL streptomycin sulfate. Cell type-specific culture conditions include: (1) Dulbecco's modified Eagle's medium (DMEM) for human brain neuroglioma H4 cells (from 37-year-old Caucasian male), as well as the GFP-LC3-expressing and ATG5 -/-derivatives, hepatocyte-derived cellular carcinoma HuH7 cells (from 57-year-old Japanese male) and hepatocyte-like CCL-13 cells (donor unknown); (2) Eagle minimum essential medium (EMEM) supplemented as above plus 2 mM glutamine and 1% non-essential amino acids (NEAA) for human hepatocellular carcinoma HepG2 cells (from 15-year-old Caucasian male), and the GFP-LC3-expressing derivative; (3) Williams' Medium E plus hepatocyte maintenance supplement pack for male mouse and human primary hepatocytes plateable (purchased by Thermo Fisher Scientific). Cells were seeded in 6-, 96-or 384-well plates and grown for 24 h before treatment with 10 mM rapamycin, 50 nM bafilomycin A1, alone or in combination, 1 mg/mL Brefeldin A, 50 nM chloroquine or 50 mM cycloheximide. Nutrient-free (NF) conditions were established by culturing cells in serum-free Earle's balanced salt solution (EBSS).
Neutralization and Exogenous Supply of ACBP
The following antibodies against ACBP were used in vivo (5 mg/g BW, intraperitoneally, in 200 mL) or in vitro (1-10 mg/mL): sc-30190 (polyclonal rabbit IgG antibody, Santa Cruz Biotechnology, CA, USA), ab231910 (polyclonal rabbit IgG antibody, Abcam, Cambridge, #2315-2015101617138161v1, #8530-2017011216394941v2, #10862-2017080217568517v3, France) . Male mice were kept in SPF conditions, in standard housing conditions in a temperature-controlled environment with 12 h light/dark cycles and received normal diet (ND) or high-fat diet (HFD; SAFE, Augy, France) and water ad libitum. Mice were subjected to 24 h starvation or were injected intraperitoneally or intravenously and sacrificed 1 h or 6 h later. Tissues were snap-frozen in liquid nitrogen, extracted and homogenized in 2 cycles for 20 s at 5,500 rpm using a Precellys 24 tissue homogenator (Bertin Technologies, Montigny-le-Bretonneux, France) in 20 mM Tris buffer (pH 7.4) containing 150 mM NaCl, 1% Triton X-100, 10 mM EDTA and Complete protease inhibitor cocktail (Roche Applied Science). Tissue extracts were then centrifuged at 12,000 g (4 C) and supernatants were collected. Protein concentration in supernatants was evaluated by the bicinchoninic acid technique (BCA protein assay kit, Pierce Biotechnology, Rockford, IL, USA). Recombinant mouse leptin (50 mg/Kg BW) was administered by i.p. injection. Leupeptine (15 mg/Kg BW) and dimethyl a-ketoglutarate (300 mg/Kg BW) were used in vivo by two i.p. injection, 12 h and 4 h before the end of the experiment. WZB177 (20 mg/Kg BW) was used in vivo at by i.p. administration.
Conditional ACBP Mice B6.Cg-Tg(UBC-cre/ERT2)1Ejb/1J mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). Acbp fl/fl mice in which loxP sites flank Acbp exon 2 were generated by OZgene (Bentley, WA, USA). On breeding, genotype was verified by PCR using genomic DNA isolated from tail biopsies with primer pairs specific for Cre and Acbp. Acbp primers:
(1) ACBP01F, CAAAGACCATCTCCCTAAACTC; C (7 min); 4 C. PCR products were separated by electrophoresis in 2% agarose gels and visualized using ethidium bromide.
Cre recombinase was activated by administration of Tamoxifen (i.p. 75mg/KG BW tamoxifen/mouse daily during 5 days). Tamoxifen was diluted in corn oil (90%) + Ethanol (10%) at a concentration of 20 mg/ml and shake overnight at 37 C.
ACBP Immunization
Keyhole limpet haemocyanin (KLH; from Stellar Biotechnologies, Port Hueneme, CA, USA) and mouse recACBP were mixed at a 1:20 molar ratio and adjusted gradually to 0.25% (v/v) glutaraldehyde. The reaction was terminated by addition of a glycine solution. After ultrafiltration using a 100 KDa membrane (Millipore, Billerica, MA, USA), a formaldehyde solution was added to 0.2% (v/v) final concentration. The reaction was quenched by addition of a glycine solution followed by an ultrafiltration with 70 mM phosphate buffer (pH 7.8). Male 6-8 week-old C57BL/6 mice obtained from Envigo, were immunized with intramuscular injection of 30, 30, 10, 10 mg of KLH-ACBP or KLH alone as an emulsion (1:1) with Montanide ISA-51vg (Seppic, Paris, France) on days 0, 7, 14 and 21, respectively.
In Vivo ACBP Expression by Hydrodynamic Injection
Mice were injected intravenously with plasmid cDNA (10 mg) (pCMV6 or pLIVE) in saline (8% of the body weight) via the tail vein. DNA injection was completed in less than 5 s.
ACBP Detection in Cell Cultures and Plasma Samples ACBP levels in culture supernatants were determined using a specific ELISA kit (KA0532 ACBP (Human) ELISA; from Abnova, Taipei, Taiwan). Mouse plasma was harvested from blood collection tubes by centrifugation at 15,000 rpm for 30 min, and ACBP levels were determined by ELISA (MBS2025156; from MyBioSource, San Diego, CA, USA) as instructed by the manufacturer. Human plasma ACBP levels were measured in three different cohorts of patients, one from anorexia nervosa patients (samples from Hô pital Sainte-Anne, Paris, France) and two from obese patients (samples from Pitié -Salpê triè re Hospital, Paris, France (Cotillard et al., 2013) and Genomic Institute for Diabetes, Lille, France (Lassailly et al., 2015) , by means of the KA0532 ACBP (Human) ELISA kit. The subjects of the surgical cohort were participants of the ABOS study (NCT01129297), an ongoing prospective trial for the longitudinal assessment of metabolic outcomes before and after gastric banding, an exclusively restrictive weight loss intervention. The study design has been detailed elsewhere. The institutional review board approved the study protocol and patients provided written informed consent before enrolment. All patients underwent an extensive preoperative multidisciplinary evaluation according to French recommendations. Clinical and biological features were assessed preoperatively and at 1 year after surgery. Study outcomes were weight, body mass index (BMI). Circulating insulin was measured at baseline.
Peripheral Blood Mononuclear Cells Isolation
To prepare peripheral blood mononuclear cells from healthy male and female volunteers, 500 mm of total blood were diluted in 5 mL red blood cell lysis buffer (BioLegend, 420301) for 10 min at room temperature and cells were washed twice in phosphate-buffered saline (PBS; Thermo Fisher Scientific, 10010023).
Leptin, Ghrelin, Insulin, C-peptide, GIP and Adiponectin Detection in Plasma Plasma was harvested from blood collection tubes by centrifugation at 15,000 rpm for 30 min, and stored at À80 C until use. Leptin, ghrelin, insulin, C-peptide, GIP and adiponectin levels were measured using a mouse serum adipokine immunoassay kit following the protocol provided by the manufacturers.
Plasmid Transfection and RNA Interference ACBP-encoding plasmids were obtained from OriGene (Rockville, MD, USA). Transient plasmid transfections were performed with the AttracteneR reagent (Qiagen, Hilden, Germany), and, unless otherwise indicated, cells were analyzed 24 h after transfection. Cells were cultured in 6-or 96-wells plates and transfected at 50-60% confluence. siRNAs were reverse-transfected with the help of the RNAi MaxTM transfection reagent (Invitrogen, Eugene, USA) in the presence of 100 nM of siRNAs specific for ACBP or SMARTpool siRNAs against STX3, STX4, TRIM10, SNAP29, SNAP23, TRIM16, SEC22B, ATG5, ATG7, ATG10, and BECN1 (Qiagen) for 48-96 h. The cells were treated as described and processed for cytofluormetric analysis to assess ACBP levels, or autophagy detection by fluorescent microscopy or western blot analysis. (Qiagen). A scrambled siRNA (SCR) was used as a control, and siRNA-mediated protein downregulation was controlled by immunoblotting.
Cytofluorimetric Assays
Cells were collected using Accutase (StemPro Accutase Cell Dissociation Reagent, ThermoFisher, ref A1110501) and washed twice with PBS upon fixation with PBS at 2% PFA for 20 min at room temperature. Cells were permeabilized with 0.1% Triton X-100 for 10 min, then washed twice with cold blocking buffer (3% bsa, v/v in PBS), followed by overnight staining with primary antibodies at 4 C. Cells were washed and incubated with secondary antibody AlexaFluor 647-conjugates in blocking buffer (for 60 min) and washed prior to flow cytometer analysis (MACSQuant cytometer (Miltenyi Biotec, Bergisch Gladbach, Germany)).
Multispectral imaging flow cytometry was performed on an AMNIS ImageStream X Mark II equipped with 375-, 488-, 561-, and 642-nm lasers using the 60x magnification lens. Only Hoechst+ events were recorded. The analysis was done with IDEAS software v6.1. Only focused events were included in the analysis, using the gradient RMS feature of bright field images. Singlets were then gated on aspect ratio vs area of bright field and leukocyte subpopulations were gated on a pictogram indicating the intensity of PTPRC/CD45 staining versus dark field. The intensity of ACBP staining was quantified within the entire cell.
Immunofluorescence Cells were fixed with 4% paraformaldehyde (PFA) for 15 min at room temperature, and permeabilized with 0.1% Triton X-100 for 10 min. Non-specific binding sites were blocked with 5% bovine serum in PBS, followed by overnight staining with primary antibodies at 4 C. Cells were stained for the detection of ACBP with sc-30190 (Santa Cruz Biotechnology, CA, USA). Primary antibodies were revealed with appropriate AlexaFluor conjugates (Molecular Probes-Invitrogen, Eugene, Oregon, USA). Nuclei were counterstained with 10 mM Hoechst 33342. Standard and confocal fluorescence microscopy assessments (20X/40X) were performed on an IRE2 microscope (Leica Microsystems, Wetzlar, Germany) equipped with a DC300F camera, an LSM 510 microscope (Carl Zeiss, Jena, Germany) or a Leica SPE confocal microscope (Leica Microsystems). Acquired images were converted to 8-bit binary files, and cytoplasmic ACBP intensity on each image was calculated by ImageJ software (NIH). Each experiment was done at least three times.
Automated Microscopy
Cells stably expressing GFP-LC3 were seeded in 96-or 384-well imaging plates (BD Falcon, Sparks, USA) 24 h before stimulation. Cells were treated with the indicated agents for 4-6 h. Subsequently, cells were fixed with 4% PFA and counterstained with 10 mM Hoechst 33342. Images were acquired using an ImageXpress Micro XLS Widefield High-Content Analysis System operated by the MetaXpress Image Acquisition and Analysis Software (Molecular Devices, Sunnyvale, CA, US). Acquisition was performed by means of a 20X PlanApo objective (Nikon, Tokyo, Japan). Minium 9 views fields per well for 96-well or 384-well plate were acquired. MetaXpress was utilised to segment cells into nuclear area (based on Hoechst 33342 signal). GFP-LC3+ dots number per cell are counted within each cytoplasmic ROI based on differential pixel intensity of GFP-LC3 signal. Autophagy level was measured by counting the numbers of GFP-LC3+ puncta per cell. Images were also acquired using a BD pathway 855 automated microscope (BD Imaging Systems, San José , CA, USA) equipped with a 40X objective (Olympus, Center Valley, USA) coupled to a robotized Twister II plate handler (Caliper Life Sciences, Hopkinton, USA). Images were analyzed for the presence of GFP-LC3 puncta in the cytoplasm by means of the BD Attovision software (BD Imaging Systems). Cell-like objects were segmented and divided into Sample Preparation Plasma (Lithium Heparin) A volume of 50 mL of plasma were mixed with 225 mL of MEOH into 1.5 mL microtubes, vortexed 5 minutes and centrifugated (10 min at 15000 g, 4 C). 750 mL of MTBE were added and the samples were vortexed 1 min. 188 mL of MilliQ water were added in the samples, followed by vortex (4 minutes) and centrifugation (10 min at 15000 g, 4 C). 700 mL of the organic upper phase of the supernatant were transferred in microtubes for further analysis, and the lower phase was supplemented with 1 ml of MEOH followed by vortex (5 min) and centrifugation (2 min at 14000 g). The supernatant was split in two parts: the first 300 mL used for the GC/MS experiment in microtubes, the others 700 mL used for the UHPLC/MS experimentations. Concerning the GC-MS aliquots, 250 ml were transferred from the microtubes to an injection vial and evaporated. The dried extract was stored at -80 C until derivatization and analysis. Concerning the UHPLC-MS aliquots, the collected supernatant was evaporated in microtubes at 40 C in a pneumatically-assisted concentrator (Techne DB3, Staffordshire, UK). The UHPLC-MS dried extracts were solubilized with 200 mL of MilliQ water. One aliquot of 50 mL was transferred in injection vial for direct analysis and the 150 mL were aliquoted and kept as backup at -80 C.
Labeling Experiment by Targeted Analysis of Nucleoside Phosphates and Cofactors by ion Pairing Ultra-High Performance Liquid Chromatography (UHPLC) Coupled to a Triple Quadrupole (QQQ) Mass Spectrometer Targeted analysis was performed on a RRLC 1260 system (Agilent Technologies, Waldbronn, Germany) coupled to a Triple Quadrupole 6410 (Agilent Technologies) equipped with an electrospray source operating in negative mode. The gas temperature was set to 350 C with a gas flow of 12 L/min. The capillary voltage was set to 3.5 kV. 10 mL of sample were injected on a Column Poroshell PhenylHexyl (100 mm x 2.1 mm particle size 2.7 mm) from Agilent technologies, protected by a guard column XDB-C18 (5 mm 3 2.1 mm particle size 1.8 mm) and heated at 40 C by a pelletier oven. The gradient mobile phase consisted of water with 10 mM of TBA and 10 mM AA (phase A) and Methanol with 10 mM of TBA and 10mM AA (phase B). The flow rate was set to 0.2 mL/min, and gradient as follow: initial condition was 98% phase A and 2% phase B, maintained during 1 min. Molecules were then eluted using a gradient from 2% to 70% phase B over 10 min. The column was washed using 95% mobile phase B for 2 min and equilibrated using 2% mobile phase B for 4 min. The autosampler was kept at 4 C. The collision gas was nitrogen. The scan mode used was the MRM for biological samples with the Q1 corresponding to the molecule [M-H]-and with Q3 corresponding to an expected fragment. Peak detection and integration of the isomers were performed using the Agilent Mass Hunter quantitative software (B.07.01).
